Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.750.06%
QQQ
717.860.15%
BTC/USD
79697.261.9426%
DIA
532.800.24%
GLD
406.450.08%
TLT
82.190.02%

Mirum Pharmaceuticals Inc

MIRMNASDAQ
Trade with Public
Trade with Public
$100.90
0.270.27%
At close: Sep 4, 5:00 PM EST
$100.90
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Mirum Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mirum Pharmaceuticals (MIRM).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

4S.Buy
12Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$110Upside to Avg. PT+9.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026CitizensJonathan WollebenMaintainedMarket Outperform$137
Aug 6, 2026TD CowenJoseph ThomePT CutBuy$145→$140
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target

Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137

Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $148

RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $142 to $148.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved